6,8-dichloro-4-((5-(pyridin-2-yl)-4-(3,3,3-trifluoropropyl)-4H-1,2,4-triazol-3-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one | 1313588-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6,8-dichloro-4-((5-(pyridin-2-yl)-4-(3,3,3-trifluoropropyl)-4H-1,2,4-triazol-3-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
• 英文别名: 6,8-dichloro-4-[[5-pyridin-2-yl-4-(3,3,3-trifluoropropyl)-1,2,4-triazol-3-yl]methyl]-1,4-benzoxazin-3-one
• CAS: 1313588-18-9
• 化学式: C₁₉H₁₄Cl₂F₃N₅O₂
• 分子量: 472.254
• InChiKey: GNELDGMRTGELTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  73.1
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,4-二氯-6-硝基苯酚 在 铁粉 、 potassium carbonate 、 溶剂黄146 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 6,8-dichloro-4-((5-(pyridin-2-yl)-4-(3,3,3-trifluoropropyl)-4H-1,2,4-triazol-3-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors

  摘要：

  Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.053

文献信息

• Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
  作者：Xiaohui Du、Mike Lizarzaburu、Simon Turcotte、Taeweon Lee、Joanne Greenberg、Bei Shan、Peter Fan、Yun Ling、Julio C. Medina、Jonathan Houze

  DOI：10.1016/j.bmcl.2011.04.053

  日期：2011.6

  Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1 (C) 2011 Elsevier Ltd. All rights reserved.